About Lyell Immunopharma, Inc. Common Stock
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Market Cap
$0.16B
Employees
300
Listed Since
June 17, 2021
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.lyell.comPhone
650 695-0677
Headquarters
201 HASKINS WAY
SOUTH SAN FRANCISCO, CA 94080
CIK
0001806952